Team

Who We Are

Pharma Capital Partners is led by highly experienced industry executives with extensive expertise in investment management, life science drug development, portfolio management and strategic marketing. Our senior partners have managed large R&D organizations and significant product portfolios for leading pharmaceutical and biotechnology companies. Collectively, we have been instrumental in bringing more than 60 new pharmaceutical products to the market across diverse therapeutic areas.
This depth of product development and commercial success provides us with the perspective to identify and make investments in high-value therapeutic assets and advance those assets through key value inflection points that mitigate safety risks and demonstrate therapeutic efficacy in proof-of-concept clinical studies. With more than ten decades of combined experience in all aspects of drug development, our partners have cultivated a global network of personal relationships that reach deep into the entrepreneurial, biotech, academic and pharmaceutical worlds.

Dr Radomir Julina - Managing General Partner

Radomir is Managing General Partner at Pharma Capital Partners and leads the Fund’s overall business activities. Radomir has been working in the pharmaceutical, biotech and private equity sectors for the last 25+ years. He has built a significant track record in areas ranging from pharmaceutical operations, drug development, the management of global drug development programs, and the building of efficient virtual drug development organizations, to investment finance. His experience in global private equity and virtual drug development, in particular, have helped shape the Fund’s investment approach and provides a model for success.

Prior to forming Pharma Capital Partners, Radomir was Managing Director at Celtic Pharma Management L.P., a $450 million private equity investment fund focused on evaluating and funding late-stage clinical assets. He joined Celtic Pharma Management L.P., from Protodigm Ltd., a virtual drug development company in the UK, where he was co-founder and Director. Protodigm was a spin-off from Hoffmann-La Roche AG, formed with the objective of creating and testing the accelerated novel time- and cost-efficient processes for drug development based on global strategic outsourcing and the virtual drug development company model. The Protodigm team successfully developed four novel product candidates across four different therapeutic areas from IND to NDA in less than four years – significantly beating industry benchmarks for time and funds invested.

Before Protodigm, Radomir was Head of New Molecular Entity Planning at Roche in the U.S. In this role, he worked with multidisciplinary international teams that were responsible for global strategic planning, project management and the outsourcing and partnering of large-scale global drug development programs. Before his assignment in the U.S., Radomir held various management positions at Hoffmann-La Roche AG in Switzerland in drug development, supply chain management and pharmaceutical operations. Prior, Radomir was Head of R&D and Vice-Chairman of the Board at Carbogen Laboratories AG in Switzerland, a drug development services company, which he co-founded. He holds a Ph.D. in Organic Chemistry from the University of Zurich, Switzerland. Radomir has a passion for drug development, building successful virtual organizations and investment finance.

Hugh MacMillan - General Partner & CFO

Hugh MacMillan focuses on financial management of Pharma Capital Partners’ funds and operations, and deal negotiations and legal structuring of PCP’s business contracts with its investors and research partners. He has twenty-five years of industry experience as a public and private equity and debt investor, investment banker, partnership operator, board member and strategy consultant.

He has developed a broad perspective, with first-hand experience of thousands of real-life case studies of developing companies' successes and mistakes, over a wide array of sectors and financial, operational, and regulatory situations.

Mr. MacMillan also brings specific strengths in strategic planning including decision tree analysis and contingent planning, factoring in multiple development and outcome scenarios for primary assets individually, and for companies and investment portfolios as a whole. He understands the fund-raising challenges for growth companies and has raised over US$1 billion in multiple investment and project-specific funds from institutional and private investors. In addition, over the past seven years prior to joining Pharma Capital Partners he developed an expertise in securities and corporate law, specifically in corporate and transactional structuring and authoring of complex contracts for entities and operations in the U.S., Canada, and Caribbean.

Prior to starting his own partnerships, he was focused on Public Company investments as Vice President for the Capital Group Companies, one of the world’s oldest and largest investment management organizations, with $1.5 trillion in assets under management. He received his BA with High Honors from Wesleyan University - with concentrations in Chemistry and Economics in 1991, an MBA with a concentration in Finance from Stanford University's Graduate School of Business in 1995, and a Chartered Financial Analyst (CFA) designation in 1999.

Reid Adler JD - Managing Director IP Strategy

Reid has been involved with intellectual property and technology transactions in the life sciences field for over 30 years. He has a long record of success in developing innovative IP strategies and designing and managing patent portfolios in a career that includes experience as a senior law firm partner, in-house general counsel, and IP strategy consultant to a major multinational pharmaceutical company.

Most recently, Reid was the founder and principal of Practical Innovation Strategy, providing program and policy support to a variety of nonprofit and for-profit clients. Previously, he was a Partner in the Washington, D.C. office of Morgan Lewis, where he was the founder and Head of the firm’s Life Sciences Patent Practice, and prior to that, he was Partner and Co-Chair of the Life Sciences Practice in the Washington, D.C. office of Morrison & Foerster. Reid also was the Chief Legal Officer and Executive Vice President of Correlogic Systems, and served as General Counsel and Risk Management Officer of the J. Craig Venter Institute and its affiliate The Institute for Genomics Research, both pioneering genomics research organizations. He was the founding Director of the NIH Office of Technology Transfer, and played a key role in developing technology transfer policies, research integrity guidelines and the Uniform Biological Material Transfer Agreement.

He holds a J.D. from the George Washington University Law School. After law school, he clerked for Judge Giles Rich at the U.S. Court of Appeals for the Federal Circuit and was a fellow at the Max Planck Institute for Foreign and International Patent, Copyright and Competition Law in Munich, Germany. Reid has testified before Congress on technology transfer policy, published numerous articles, and has taught courses in Strategic Planning, Technology Transfer, Biotechnology Patent Law and Legal Aspects of Biotechnology at The Johns Hopkins University and George Washington University Law School.

Michael G Shulman MD – Managing Director Clinical Science & Development Strategy

During a quarter century in industry drug development devoted to serious unmet medical needs, Michael was closely associated with the development, regulatory approval, or marketing launch of Neoral, CellCept, DynaCirc, Celsior, and Krystexxa® (pegloticase).

In addition to Medical Affairs responsibilities at Sandoz Pharmaceuticals Corporation and R&D roles at Syntex Development Research, Michael was Vice President, Clinical Development, at Anergen, where he designed and led first-in-human clinical trials of novel biologics for active, DMARD-refractory rheumatoid arthritis or secondary progressive multiple sclerosis. He contributed his expertise to more than 20 biopharmaceutical companies and CROs such as Sandoz, Syntex, Genentech, Chiron, Alza, SangStat, Anergen, Neurobiological Technologies, Celtic Pharmaceutical Holdings, CTI Clinical Trial & Consulting Services, Research Pharmaceutical Services, and PRA Health Sciences. He is an Emeritus Member of the American College of Rheumatology, the American Society of Nephrology, the American Society of Transplantation, and the Society for Neuro-oncology.

Michael is an experienced and versatile leader in translational medical/scientific research, as well as the design and execution of clinical trials. He has a track record of successful collaboration with academic investigators and Key Opinion Leaders, medical monitoring of global clinical trials, accompanied by positive FDA interactions and regulatory document submissions.

An MD graduate of Columbia University’s College of Physicians & Surgeons, board-certified in Internal Medicine, with subspecialty training and expertise in Nephrology, Michael was Assistant Professor of Medicine (Nephrology), Emory University School of Medicine, directed three freestanding dialysis centers, and is currently licensed in California.

David York Norton - Advisory Board & Investment Committee Member

David Y. Norton is Member of the Pharma Capital Partners Advisory Board and Member of the Fund Investment Committee. David brings a broad strategic business and commercial perspective to Pharma Capital Partners. Until his retirement in September 2011, David was Company Group Chairman, Global Pharmaceuticals for Johnson & Johnson (J&J). In this position, he was responsible for leading and developing the strategic growth agenda, including the strategy for licensing, acquisitions and divestments, and ensuring alignment with J&J’s global strategic functions, R&D and the Commercial organizations. The J&J Pharmaceuticals Group has sales in excess of US$22 Billion and represents >30% of total J&J revenues. David began his J&J career in 1979 as a product manager for the company's affiliate Janssen Pharmaceutica in Australia.

Among his outside activities, David is the immediate past Chairman of the Board of Directors of the American Foundation for Suicide Prevention, a current Director of the Global Alliance for TB Drug Development and Vivus Inc., and a Senior Advisor to Tapestry Networks. He previously served as a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) from 2006 to 2010 and was Treasurer during the final year.

The right people, pursuing the right ideas, powered by the right investment vehicle